Tech Company Financing Transactions

Tubulis Funding Round

Venrock Healthcare Capital Partners, Andera Partners and Ascenta Capital joined a $361 million Series C funding round for Tubulis. The round closed on 10/15/2025.

Transaction Overview

Company Name
Tubulis
Announced On
10/15/2025
Transaction Type
Venture Equity
Amount
$361,000,000
Round
Series C
Investors

Venrock Healthcare Capital Partners (Lead Investor)

Andera Partners (Sofia Ioannidou)

Ascenta Capital (Lorence Kim)

Bayern Kapital

Deep Track Capital

EQT Life Sciences (Christoph Broja)

Frazier Life Sciences (Patrick Heron)

Fund+

High-Tech Gründerfonds

Nextech Invest (Kanishka Pothula)

OCCIDENT

Seventure Partners

Wellington Management Company

Proceeds Purpose
The company intends to use the proceeds to expand the clinical development of TUB-040, its lead antibody-drug conjugate (ADC) candidate, into earlier lines of therapy and additional tumor indications, advance its pipeline, including the clinical-stage ADC candidate TUB-030, several preclinical programs, and expand its proprietary ADC platform technologies to bring ADCs into novel applications.

Company Information

Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Butenandtstraße 1
Munich, 81377
Germany
Phone
Undisclosed
Website
www.tubulis.com
Email Address
[email protected]
Overview
Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication.
Profile
Tubulis LinkedIn Company Profile
Social Media
Tubulis Company Twitter Account
Company News
Tubulis News
Facebook
Tubulis on Facebook
YouTube
Tubulis on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Dominik Schumacher
  Dominik Schumacher LinkedIn Profile  Dominik Schumacher Twitter Account  Dominik Schumacher News  Dominik Schumacher on Facebook
Chief Marketing Officer
Günter Fingerle-Rowson
  Günter Fingerle-Rowson LinkedIn Profile  Günter Fingerle-Rowson Twitter Account  Günter Fingerle-Rowson News  Günter Fingerle-Rowson on Facebook
Chief Scientific Officer
Jonas Helma-Smets
  Jonas Helma-Smets LinkedIn Profile  Jonas Helma-Smets Twitter Account  Jonas Helma-Smets News  Jonas Helma-Smets on Facebook
Vice President
Olivier Marcq
  Olivier Marcq LinkedIn Profile  Olivier Marcq Twitter Account  Olivier Marcq News  Olivier Marcq on Facebook
VP - Bus. Development
Ingo Lehrke
  Ingo Lehrke LinkedIn Profile  Ingo Lehrke Twitter Account  Ingo Lehrke News  Ingo Lehrke on Facebook
VP - Regulatory Affairs
Armin Weidmann
  Armin Weidmann LinkedIn Profile  Armin Weidmann Twitter Account  Armin Weidmann News  Armin Weidmann on Facebook

 

 

Browse more venture capital transactions:

Prev: 10/15/2025: Mission Therapeutics venture capital transaction
Next: 10/15/2025: Flow Engineering venture capital transaction

 

Share this article

 

News on VC Transactions

We report on funding rounds that are announced publicly. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2025. Gaebler Ventures. All rights reserved.